Skip to content

Study on Clinical, pathological and TCM Syndromes of IgA Nephropathy with malignant Hypertension

Study on Clinical, pathological and TCM Syndromes of IgA Nephropathy with malignant Hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200005559
Enrollment
Unknown
Registered
2022-01-26
Start date
2022-01-12
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgAN,malignant hypertension

Interventions

Sponsors

Chinese PLA General Hosptial
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) this study was approved by the ethics committee of the first medical center of the PLA General Hospital (ethics approval No.: s2021-165-01). The retrospective patients were exempted from signing informed consent, and the prospective patients voluntarily participated in this study and signed informed consent. (2) After 2013, patients with primary IgA nephropathy diagnosed by renal biopsy in the Department of Nephrology of the first medical center of the PLA General Hospital. (3) In hospital diagnosis of renal puncture with malignant hypertension [10], that is, the blood pressure is significantly elevated, usually > 200 / 120mmhg, and can be accompanied by significant bilateral retinopathy (flame hemorrhage, cotton wool spots or optic papilledema). (4) The age of renal biopsy was over 18 years old (including 18 years old), regardless of gender; (5) There was a questionnaire of traditional Chinese medicine within 7 days before and after renal biopsy.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) the number of evaluable glomeruli was less than 8; (2) Secondary IgA nephropathy such as purpura nephritis, lupus nephritis and hepatitis B; (3) Other renal diseases such as membranous nephropathy; (4) combined with diabetes, connective tissue disease and other systemic diseases. (5) The medical records are incomplete.

Design outcomes

Primary

MeasureTime frame
no;

Countries

China

Contacts

Public Contactkejianghua
1585827227@qq.com19860782356

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026